Bausch + Lomb (B + L) has acquired an exclusive global license to a technology that may lead to a faster, more effective, and longer-lasting treatment for ocular redness.
Madison, NJ-Bausch + Lomb (B + L) has acquired an exclusive global license to a new-platform technology that may lead to a faster, more effective, and longer-lasting treatment for ocular redness.
The technology uses a uniquely formulated low dose of brimonidine to relieve ocular redness, a different mechanism of action from currently available products. The technology is licensed from Eye Therapies, LLC, a privately held biopharmaceutical company, and was developed in collaboration with Ora Inc., a private research organization.
“Ocular redness is associated with reduced quality of life and negative social connotations, and may [affect] compliance with certain medications,” explained Dr. Cal Roberts, chief medical officer, Bausch + Lomb. “The decision to license this promising new technology underscores our continued commitment to delivering solutions for physicians and their patients.”
“We are proud to be working with Bausch + Lomb to develop this promising new technology,” said Lee Nordan, MD, chief executive officer of Eye Therapies, LLC. “The company’s commitment, expertise, and resources, combined with its global reach, will help ensure that, if approved, this technology will reach its full potential.”
For more articles in this issue of Ophthalmology Times eReport,click here.